Clinical trial
A Study to Evaluate the Effects of Rituximab on Immune Responses in Subjects…
NCT00282308 · Genentech, Inc., Industry · Completed
Key facts
| NCT number | NCT00282308 |
|---|---|
| Title | A Study to Evaluate the Effects of Rituximab on Immune Responses in Subjects With Active Rheumatoid Arthritis Receiving Background Methotrexate |
| Official title | A Phase II, Randomized, Parallel-group, Open-label, Multicenter Study to Evaluate the Effects of Rituximab on Immune Responses in Subjects With Active Rheumatoid Arthritis Receiving Background Methotrexate |
| Acronym | SIERRA |
| Lead sponsor | Genentech, Inc., Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Rheumatoid Arthritis |
| Intervention type | Biological, Drug |
| Interventions | Rituximab, Methotrexate, Methylprednisone, C. albicans, Tetanus toxoid adsorbed booster vaccine, 23-valent pneumococcal polysaccharide vaccine, Keyhole limpet hemocyanin |
| Enrollment | 103 |
| Start date | Jan 23, 2006 |
| Primary completion | Jan 31, 2008 |
| Completion | May 28, 2012 |
| First posted | Jan 26, 2006 |
| Last update posted | Aug 10, 2017 |
| Countries | United States |
At a glance
- 10–99 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: